David D. Moore

38.1k citations

286 papers · 27.8k indexed · 8 hit papers · h-index 92

Pharmacology top 0.01%
- Pharmacogenetics and Drug Metabolism 36
Endocrinology, Diabetes and Metabolism top 0.1%
Oncology top 0.1%
- Drug Transport and Resistance Mechanisms 64
Genetics top 0.05%
- Estrogen and related hormone effects 46
Aging top 0.5%
Surgery
- Cholesterol and Lipid Metabolism 29
Epidemiology
- Liver Disease Diagnosis and Treatment 28
Molecular Biology
- Retinoids in leukemia and cellular processes 26
- Peroxisome Proliferator-Activated Receptors 22
Cellular and Molecular Neuroscience
- Nuclear Receptors and Signaling 22

Co-authors: Wendong Huang Wongi Seol Hueng-Sik Choi Dennis H. Dowhan Mohammed Qatanani Gregory A. Brent Yoon‐Kwang Lee Iphigenia Tzameli
Cited by: Pharmacology Endocrinology, Diabetes and Metabolism Oncology
Journals: Molecular Endocrinology (23 papers)Hepatology (19 papers)Journal of Biological Chemistry (18 papers)
Partner nations: United States South Korea China

In The Last Decade

David D. Moore

281 papers receiving 27.0k citations

Hit Papers

8 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2016 Cell
2016 Cancer Cell
2014 Nature
2006 Science
2000 Nature
1999 Science
1986 Molecular and Cellular Biology
1977 Science

Peers

Countries citing papers authored by David D. Moore

Since Specialization

Citations

This map shows the geographic impact of David D. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David D. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David D. Moore more than expected).

Fields of papers citing papers by David D. Moore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David D. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David D. Moore. The network helps show where David D. Moore may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David D. Moore, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David D. Moore Line = papers co-authored together David D. Moore links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model Journal of Hepatology ·Branko Ursić,I A Eltayeb,Beatrice Bissig-Choisat,Sandra L. Grimm,Xuan Qin,Angela M. Major,Li Yang,Dolores López‐Terrada,Cristian Coarfa,Feng Li,Karl‐Dimiter Bissig,David D. Moore,Loning Fu	2023	31
2	MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade Nature Communications ·Wei Wang,Nikolay A. Kapridov,Qinbo Cai,Tao Shen,Bingning Dong,Michael T. Lewis,Runsheng Wang,Yan–Ling Meng,Wolong Zhou,Ping Yi,Chad J. Creighton,David D. Moore,Feng Yang	2022	35
3	A phospholipid mimetic targeting LRH-1 ameliorates colitis Cell chemical biology ·T. Salazar,Emma H. D’Agostino,M Gehrisch,Xiangsheng Huang,Guohui Wang,Xu Liu,Eamon Duffy,C. Denise Okafor,Anamika Patel,John Charles Torres Vásquez,Antoine Gallet,Diana Melchers,René Houtman,David D. Moore,John W. Calvert,Nathan T. Jui,Eric A. Ortlund	2022	9
4	Vertical sleeve gastrectomy confers metabolic improvements by reducing intestinal bile acids and lipid absorption in mice Proceedings of the National Academy of Sciences ·Lili Ding,Eryun Zhang,Qiaoling Yang,Lihua Jin,Kyle M. Sousa,Bingning Dong,Yangmeng Wang,Jui Tu,Xiaoxiao Ma,Jingyan Tian,Hongli Zhang,Zhipeng Fang,Daniel Domingo Zuñiga Castro,Yixin Zhang,Zhengtao Wang,David D. Moore,Li Yang,Wendong Huang	2021	36
5	MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT Journal of Clinical Investigation ·Tao Shen,Wei Wang,Wolong Zhou,Ilsa M. Coleman,Qinbo Cai,Bingning Dong,Michael Ittmann,Chad J. Creighton,Yingnan Bian,Yan–Ling Meng,David R. Rowley,Peter S. Nelson,David D. Moore,Feng Yang	2021	43
6	MAPK6-AKT signaling promotes tumor growth and resistance to mTOR kinase blockade Science Advances ·Qinbo Cai,Wolong Zhou,Wei Wang,Bingning Dong,Nikolay A. Kapridov,Tao Shen,Chad J. Creighton,David D. Moore,Feng Yang	2021	23
7	CAR directs T cell adaptation to bile acids in the small intestine Nature ·Mei Lan Chen,Xiangsheng Huang,Hongtao Wang,G. Haberlandt,Yujin Liu,Jinsai Shang,Mi-Jung Jung,Huitian Diao,HaJeung Park,Blake Frey,Guohui Wang,Sarah A. Mosure,Laura A. Solt,Douglas J. Kojetin,Alexander Rodriguez‐Palacios,Deborah Schady,Casey T. Weaver,Matthew E. Pipkin,David D. Moore,Mark S. Sundrud	2021	61
8	The bile acid induced hepatokine orosomucoid suppresses adipocyte differentiation Biochemical and Biophysical Research Communications ·Sung Ho Lee,Jong Min Choi,Sung Yun Jung,Aaron R. Cox,Sean M. Hartig,David D. Moore,Kang Ho Kim	2020	13
9	Integrated Genomic Comparison of Mouse Models Reveals Their Clinical Resemblance to Human Liver Cancer Molecular Cancer Research ·Sun Young Yim,Jae‐Jun Shim,Ji-Hyun Shin,Yun Seong Jeong,Sanghee Kang,Sang-Bae Kim,Young‐Gyu Eun,Dong Jin Lee,Elizabeth A. Conner,Valentina M. Factor,David D. Moore,Randy L. Johnson,Snorri S. Thorgeirsson,Ju‐Seog Lee	2018	16
10	Constitutive Androstane Receptor Differentially Regulates Bile Acid Homeostasis in Mouse Models of Intrahepatic Cholestasis Hepatology Communications ·Kang Ho Kim,Jong Min Choi,Feng Li,Bingning Dong,Clavia Ruth Wooton‐Kee,Marcos Furiati,Sayeepriyadarshini Anakk,Sung Yun Jung,Sean M. Hartig,David D. Moore	2018	19
11	Compensatory changes in CYP expression in three different toxicology mouse models: CAR-null, Cyp3a-null, and Cyp2b9/10/13-null mice PLoS ONE ·Oleksii Horchakov,Linda C. Mota,W. Wesolowska,John P. Rooney,William Boswell,Ivan S. Zhndro,Charles M. Henderson,Juan Pablo Rojas Hernández,J. Christopher Corton,David D. Moore,William S. Baldwin	2017	32
12	Glucocorticoids Have Opposing Effects on Liver Fibrosis in Hepatic Stellate and Immune Cells Molecular Endocrinology ·Kang Ho Kim,Jae Man Lee,Ying Zhou,Sanjiv Harpavat,David D. Moore	2016	24
13	Orphan Nuclear Receptor ERRα Controls Macrophage Metabolic Signaling and A20 Expression to Negatively Regulate TLR-Induced Inflammation Immunity ·Jae–Min Yuk,Tae Sung Kim,Soo Yeon Kim,Hyemi Lee,Jeongsu Han,Catherine R. Dufour,Jin Kyung Kim,Hyo Sun Jin,Chul‐Su Yang,Ki-Sun Park,Chul‐Ho Lee,Jin‐Man Kim,Gi Ryang Kweon,Hueng‐Sik Choi,Jean-Marc Vanacker,David D. Moore,Vincent Giguère,Eun‐Kyeong Jo	2015	106
14	Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs American Journal of Physiology-Gastrointestinal and Liver Physiology ·Ajay K. Jain,Barbara J. Stoll,Douglas G. Burrin,Jens J. Holst,David D. Moore	2011	104
15	Absence of the SRC-2 Coactivator Results in a Glycogenopathy Resembling Von Gierke's Disease Science ·Atul R. Chopra,Jean‐François Louet,Pradip Saha,Jie An,Francesco J. DeMayo,Jianming Xu,Brian York,Saul J. Karpen,Milton J. Finegold,David D. Moore,Lawrence Chan,Christopher B. Newgard,Bert W. O’Malley	2008	133
16	Adamantyl-Substituted Retinoid-Related Molecules Bind Small Heterodimer Partner and Modulate the Sin3A Repressor Cancer Research ·Lulu Farhana,Marcia I. Dawson,Mark Leid,Li Wang,David D. Moore,Gang Liu,元庭山,Joseph A. Fontana	2007	63
17	Spontaneous Development of Liver Tumors in the Absence of the Bile Acid Receptor Farnesoid X Receptor Cancer Research ·Fan Yang,Xiongfei Huang,Tangsheng Yi,Yun Yen,David D. Moore,Wendong Huang	2007	393
18	A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR Science ·Jennifer A Madigan,Jean-Claude Rochigneux,van den Broek Ta,Peter Kihl,Peter Ordentlich,Yingzhuo Yan,Frank J. Gonzalez,Richard A. Heyman,David J. Mangelsdorf,David D. Moore	2002	437
19	The Orphan Nuclear Receptor SHP Inhibits Hepatocyte Nuclear Factor 4 and Retinoid X Receptor Transactivation: Two Mechanisms for Repression Molecular and Cellular Biology ·Yoon‐Kwang Lee,Helen Dell,Dennis H. Dowhan,Margarita Hadzopoulou‐Cladaras,David D. Moore	2000	249
20	Inhibition of Estrogen Receptor Action by the Orphan Receptor SHP (Short Heterodimer Partner) Molecular Endocrinology ·Wongi Seol,Bettina Hanstein,Myles Brown,David D. Moore	1998	124

About David D. Moore

David D. Moore is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Genetics, having authored 286 papers that have together received 27.8k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (64 papers), Estrogen and related hormone effects (46 papers), Pharmacogenetics and Drug Metabolism (36 papers), Cholesterol and Lipid Metabolism (29 papers), Liver Disease Diagnosis and Treatment (28 papers), Retinoids in leukemia and cellular processes (26 papers), Nuclear Receptors and Signaling (22 papers) and Peroxisome Proliferator-Activated Receptors (22 papers). The work is most often cited by research in Pharmacology (4.3k citations), Endocrinology, Diabetes and Metabolism (5.0k citations) and Oncology (8.0k citations). David D. Moore has collaborated with scholars based in United States, South Korea and China. Frequent co-authors include Wendong Huang, Wongi Seol, Hueng-Sik Choi, Dennis H. Dowhan, Mohammed Qatanani, Gregory A. Brent, Yoon‐Kwang Lee, Iphigenia Tzameli, John W. Harney and Ping Wei. Their work appears in journals such as Molecular Endocrinology, Hepatology, Journal of Biological Chemistry, Current Protocols in Molecular Biology and Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact